The impact of the affordable care act on breast cancer care in the USA: A multi-institutional analysis.

There are less data available on the effect of the ACA on breast cancer care beyond the screening level. A retrospective review at participating iCaRe2/BCCR institutions was completed before and after ACA. Post-ACA, patients were older, more urban, and more likely to be insured through Medicaid.

Incarceration among adults who are in the public mental health system: rates, risk factors, and short-term outcomes.

Objective: Incarceration of people with mental illness has become a major social, clinical, and economic concern, with an estimated 2.1 million incarcerations in 2007. Prior studies have primarily focused on mental illness rates among incarcerated persons.

A peer-driven mentoring case management community reentry model: an application for jails and prisons.

Welcome Home Ministries (WHM) is a peer-driven reentry program for women reentering the community from jail and prison. One of the major contributing factors to a high recidivism rate is the presenting issue of co-occurring disorders stemming from early childhood abuse and trauma found in 85% of the women seeking the assistance of WHM. The peers within WHM, having experienced mental health issues, substance abuse, and incarceration themselves, identified and developed a specific reentry program for this population.

A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.

Diarrhea is a well-recognized side effect of chemotherapy and can result in chemotherapy delay and/or dose reduction, potentially reducing the therapeutic benefit of treatment. Octreotide has been shown to be effective in controlling chemotherapy-induced diarrhea (CID). In this open-label, randomized, multicenter study, designed to asses the effects of two dose levels of octreotide long-acting release (LAR), patients with active or prior CID and scheduled for chemotherapy were randomized to receive up to six doses of either 30 or 40 mg of octreotide LAR.